Clinical therapeutics
-
Clinical therapeutics · Jan 1981
Comparative Study Clinical Trial Controlled Clinical TrialComparative trial of intravenous lorazepam and clonazepam im status epilepticus.
The primary use of lorazepam, when administered intravenously (IV), has been in the treatment of acute attacks of anxiety and agitation. Recent studies have investigated its efficacy in patients with status epilepticus. The present study compared the efficacy and tolerability of lorazepam and clonazepam in the treatment of status epilepticus. ⋯ Both drugs were most effective in patients with secondary generalized epilepsy. Drowsiness followed either drug. Psychomotor agitation followed either drug in 12% of patients.
-
Clinical therapeutics · Jan 1981
Comparative Study Clinical TrialKetamine fro postoperative analgesia after upper abdominal surgery.
-
The suitability of lorazepam as a sedative for use in intensive care has been critically evaluated in 36 severely ill patients. The efficacy of lorazepam has been evaluated by regular measurements of both cardiovascular and neurological status as well as by the nursing staff directly involved with the care of the patients. ⋯ The benefits of the predictable and even sedation produced by a long-acting drug of this nature are discussed. Particular attention has been paid to the possibility of accumulation of lorazepam in a similar way to that of diazepam, and the relative advantages of the two drugs for use in the intensive care situation have been compared.
-
Clinical therapeutics · Jan 1981
The effect of ranitidine hydrochloride, a new histamine H2-receptor antagonist, on intrinsic factor secretion.
The effect on intrinsic factor (IF) secretion of eight weeks' continuous treatment with a clinically relevant oral dose of ranitidine hydrochloride, a new histamine H2-receptor antagonist, has been studied in 11 patients with duodenal ulcer. There was no significant difference between the mean IF output during treatment of after drug withdrawal as compared with the control value, despite highly significant (p less than 0.001) reduction in acid output during treatment. In the short term this potent drug is unlikely to cause pernicious anemia from interference with IF secretion, although further study is necessary to exclude this possibility after long-term use.